Inhibrx (NASDAQ:INBX – Get Free Report) released its earnings results on Monday. The company reported ($3.09) earnings per share (EPS) for the quarter, missing the consensus estimate of ($2.88) by ($0.21), Zacks reports. The firm had revenue of $0.10 million during the quarter.
Inhibrx Price Performance
Shares of INBX stock opened at $14.00 on Wednesday. The business’s 50-day moving average price is $13.30 and its 200-day moving average price is $14.66. Inhibrx has a 12 month low of $10.80 and a 12 month high of $35.42.
Wall Street Analysts Forecast Growth
Separately, JMP Securities reaffirmed a “market perform” rating on shares of Inhibrx in a research note on Wednesday, January 22nd.
About Inhibrx
Inhibrx, Inc, a clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidate includes INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency.
Read More
- Five stocks we like better than Inhibrx
- Are Penny Stocks a Good Fit for Your Portfolio?
- 3 Stocks Returning Billions to Shareholders via Buybacks
- Dividend Capture Strategy: What You Need to Know
- Tesla: 1 Reason to Love It, 1 Reason to Be Cautious
- What is diluted earnings per share (Diluted EPS)?
- 3 Stocks That Could Win Big From a 10% Cap on Credit Card Rates
Receive News & Ratings for Inhibrx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inhibrx and related companies with MarketBeat.com's FREE daily email newsletter.
